{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:00:03Z","timestamp":1785862803839,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"the healthcare business of Merck KGaA, Darmstadt, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s11523-024-01038-z","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T11:01:41Z","timestamp":1710586901000},"page":"191-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK"],"prefix":"10.1007","volume":"19","author":[{"given":"Rachael","family":"Batteson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie","family":"Wheat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Hatswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Vioix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatia Theodora","family":"Alexopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobhit","family":"Baijal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"issue":"3","key":"1038_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"1038_CR2","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jtho.2016.03.025","volume":"11","author":"WD Travis","year":"2016","unstructured":"Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB, et al. The IASLC Lung Cancer Staging Project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2016;11(8):1204\u201323.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1038_CR3","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1097\/JTO.0b013e3181b28fb9","volume":"4","author":"SH Ou","year":"2009","unstructured":"Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol. 2009;4(10):1202\u201311.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1038_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","volume":"12","author":"M Chevallier","year":"2021","unstructured":"Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol. 2021;12(4):217\u201337.","journal-title":"World J Clin Oncol."},{"issue":"8","key":"1038_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220670","volume":"14","author":"J Lung","year":"2019","unstructured":"Lung J, Hung MS, Lin YC, Lee KF, Jiang YY, Huang SL, et al. MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population. PLoS ONE. 2019;14(8): e0220670.","journal-title":"PLoS ONE"},{"issue":"6","key":"1038_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","volume":"18","author":"PM Comoglio","year":"2018","unstructured":"Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018;18(6):341\u201358.","journal-title":"Nat Rev Cancer"},{"key":"1038_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.lungcan.2019.05.011","volume":"133","author":"MM Awad","year":"2019","unstructured":"Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019;133:96\u2013102.","journal-title":"Lung Cancer"},{"issue":"10","key":"1038_CR8","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1093\/annonc\/mdy334","volume":"29","author":"JK Sabari","year":"2018","unstructured":"Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;29(10):2085\u201391.","journal-title":"Ann Oncol"},{"key":"1038_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.lungcan.2016.10.010","volume":"102","author":"AM Chapman","year":"2016","unstructured":"Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer. 2016;102:122\u201334.","journal-title":"Lung Cancer"},{"key":"1038_CR10","unstructured":"National Comprehensive Cancer Network. NCCN guidelines 2023. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450. Accessed 18 Feb 2024."},{"issue":"Suppl. 4","key":"1038_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):192\u2013237.","journal-title":"Ann Oncol"},{"issue":"8","key":"1038_CR12","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321\u20138.","journal-title":"Ann Oncol"},{"issue":"3","key":"1038_CR13","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.21873\/invivo.11920","volume":"34","author":"JY Hur","year":"2020","unstructured":"Hur JY, Ku BM, Shim JH, Jung HA, Sun JM, Lee SH, et al. Characteristics and clinical outcomes of non-small cell lung cancer patients in Korea with MET exon 14 skipping. In Vivo. 2020;34(3):1399\u2013406.","journal-title":"In Vivo"},{"issue":"10","key":"1038_CR14","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383(10):931\u201343.","journal-title":"N Engl J Med"},{"key":"1038_CR15","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). Summary of product characteristics: TEPMETKO 2021. Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/d9ea0989d5988892d2ff6ac6ec36b73871f0e4db. Accessed 18 Feb 2024."},{"key":"1038_CR16","unstructured":"US Food and Drug Administration. Highlights of prescribing information for Tepmetko\u00ae (tepotinib) tablets. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214096s000lbl.pdf. Accessed 18 Feb 2024."},{"key":"1038_CR17","unstructured":"National Institute of Health and Care Excellence (NICE). TA789: tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations 2022. Available from: https:\/\/www.nice.org.uk\/guidance\/ta789. Accessed 18 Feb 2024."},{"key":"1038_CR18","unstructured":"Scottish Medicines Consortium (SMC). SMC2535: tepotinib (Tepmetko) 2023. Available from: https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/tepotinib-tepmetko-resub-smc2535\/. Accessed 18 Feb 2024."},{"issue":"9","key":"1038_CR19","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","volume":"9","author":"J Mazieres","year":"2023","unstructured":"Mazieres J, Paik PK, Garassino MC, Le X, Sakai H, Veillon R, et al. Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial. JAMA Oncol. 2023;9(9):1260\u20136.","journal-title":"JAMA Oncol"},{"key":"1038_CR20","unstructured":"National Institute of Health and Care Excellence (NICE). TA347: nintedanib for previously treated locally advanced, metastatic, or locally recurrent non\u2011small\u2011cell lung cancer 2015. Available from: https:\/\/www.nice.org.uk\/guidance\/ta347. Accessed 18 Feb 2024. Accessed 18 Feb 2024."},{"key":"1038_CR21","unstructured":"National Institute of Health and Care Excellence (NICE). TA402: pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin 2016. Available from: https:\/\/www.nice.org.uk\/guidance\/ta402. Accessed 18 Feb 2024."},{"key":"1038_CR22","unstructured":"National Institute of Health and Care Excellence (NICE). TA428: pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy 2017. Available from: https:\/\/www.nice.org.uk\/guidance\/ta428. Accessed 18 Feb 2024."},{"key":"1038_CR23","unstructured":"National Institute of Health and Care Excellence (NICE). TA520: atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy 2018. Available from: https:\/\/www.nice.org.uk\/guidance\/ta520. Accessed 18 Feb 2024."},{"key":"1038_CR24","unstructured":"National Institute of Health and Care Excellence (NICE). TA531: pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer 2018. Available from: https:\/\/www.nice.org.uk\/guidance\/ta531. Accessed 18 Feb 2024."},{"key":"1038_CR25","unstructured":"National Institute of Health and Care Excellence (NICE). TA584: atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer 2019. Available from: https:\/\/www.nice.org.uk\/guidance\/ta584. Accessed 18 Feb 2024."},{"key":"1038_CR26","unstructured":"National Institute of Health and Care Excellence (NICE). TA600: pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer 2019. Available from: https:\/\/www.nice.org.uk\/guidance\/ta600. Accessed 18 Feb 2024."},{"key":"1038_CR27","unstructured":"National Institute of Health and Care Excellence (NICE). TA655: nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy 2020. Available from: https:\/\/www.nice.org.uk\/guidance\/ta655. Accessed 18 Feb 2024."},{"key":"1038_CR28","unstructured":"National Institute of Health and Care Excellence (NICE). TA683: pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer 2021. Available from: https:\/\/www.nice.org.uk\/guidance\/ta683. Accessed 18 Feb 2024."},{"key":"1038_CR29","unstructured":"National Institute of Health and Care Excellence (NICE). NICE health technology evaluations: the manual 2022. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation. Accessed 18 Feb 2024."},{"key":"1038_CR30","unstructured":"National Institute of Health and Care Excellence (NICE). NG122: lung cancer: diagnosis and management 2023. Available from: https:\/\/www.nice.org.uk\/guidance\/ng122. Accessed 18 Feb 2024."},{"issue":"7","key":"1038_CR31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","volume":"32","author":"D Rodr\u00edguez-Abreu","year":"2021","unstructured":"Rodr\u00edguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881\u201395.","journal-title":"Ann Oncol"},{"issue":"21","key":"1038_CR32","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small cell lung cancer with PD-L1 tumor proportion score \u2265 50. J Clin Oncol. 2021;39(21):2339\u201349.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1038_CR33","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.jval.2022.09.173","volume":"25","author":"H Vioix","year":"2022","unstructured":"Vioix H, Hatswell A, McLean T, Day C, Batteson R, Hook E, et al. CO94 Tepotinib compared with chemoimmunotherapy in first-line non-small cell lung cancer (NSCLC): matching adjusted indirect comparison (MAIC) of VISION in MET exon 14 (METex14) skipping NSCLC and KEYNOTE-189 in Wild-type NSCLC. Value Health. 2022;25(12):S36.","journal-title":"Value Health."},{"issue":"2","key":"1038_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","volume":"15","author":"M Reck","year":"2014","unstructured":"Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143\u201355.","journal-title":"Lancet Oncol"},{"issue":"9944","key":"1038_CR35","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665\u201373.","journal-title":"Lancet"},{"issue":"12","key":"1038_CR36","doi-asserted-by":"publisher","first-page":"S458","DOI":"10.1016\/j.jval.2022.09.2276","volume":"25","author":"R Batteson","year":"2022","unstructured":"Batteson R, Hook E, Vioix H, Hatswell A. RWD51 demonstrating internal and external validity in real-world datasets: a case study in MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC). Value Health. 2022;25(12):S458.","journal-title":"Value Health."},{"key":"1038_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"1038_CR38","unstructured":"Latimer N. NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials: extrapolations with patient-level data 2013. Available from: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf. Accessed 18 Feb 2024."},{"issue":"5","key":"1038_CR39","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health."},{"key":"1038_CR40","unstructured":"National Institute of Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed 18 Feb 2024."},{"issue":"8","key":"1038_CR41","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jval.2023.02.007","volume":"26","author":"M Yang","year":"2023","unstructured":"Yang M, Vioix H, Hook ES, Hatswell AJ, Batteson RL, Gaumond BR, et al. Health utility analysis of tepotinib in patients with non-small cell lung cancer harboring MET exon 14 skipping. Value Health. 2023;26(8):1155\u201363.","journal-title":"Value Health."},{"issue":"14","key":"1038_CR42","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G, Esteban E, Felip E, D\u00f3mine M, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(14):1505\u201317.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1038_CR43","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jtho.2019.12.129","volume":"15","author":"F Guisier","year":"2020","unstructured":"Guisier F, Dubos-Arvis C, Vi\u00f1as F, Doubre H, Ricordel C, Ropert S, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01\u20132018. J Thorac Oncol. 2020;15(4):628\u201336.","journal-title":"J Thorac Oncol"},{"issue":"10183","key":"1038_CR44","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330.","journal-title":"Lancet"},{"issue":"10","key":"1038_CR45","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","volume":"16","author":"RS Herbst","year":"2021","unstructured":"Herbst RS, Garon EB, Kim DW, Cho BC, Gervais R, Perez-Gracia JL, et al. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J Thorac Oncol. 2021;16(10):1718\u201332.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"1038_CR46","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro CJ, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723\u201333.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1038_CR47","doi-asserted-by":"publisher","first-page":"6306","DOI":"10.1038\/s41598-021-85696-3","volume":"11","author":"CM Cramer-van der Welle","year":"2021","unstructured":"Cramer-van der Welle CM, Verschueren MV, Tonn M, Peters BJM, Schramel F, Klungel OH, et al. Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. Sci Rep. 2021;11(1):6306.","journal-title":"Sci Rep"},{"issue":"12","key":"1038_CR48","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s40273-018-0697-3","volume":"36","author":"AJ Hatswell","year":"2018","unstructured":"Hatswell AJ, Bullement A, Briggs A, Paulden M, Stevenson MD. Probabilistic sensitivity analysis in cost-effectiveness models: determining model convergence in cohort models. Pharmacoeconomics. 2018;36(12):1421\u20136.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"1038_CR49","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.jval.2022.09.103","volume":"25","author":"A Hatswell","year":"2022","unstructured":"Hatswell A, Batteson R, Hook E, Wheat H, Vioix H, McLean T, et al. CO23 Validating the results of a matching adjusted indirect comparison (MAIC) in MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC). Value Health. 2022;25(12):S21\u20132.","journal-title":"Value Health."},{"issue":"22","key":"1038_CR50","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01038-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01038-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01038-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T10:52:21Z","timestamp":1711363941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01038-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01038-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"27 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Merck (CrossRef Funder ID: 10.13039\/100009945). Medical writing support was provided by Delta Hat and funded by Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Helene Vioix and Stamatia Theodora Alexopoulos are employees of Merck. At the time of the analyses, Thomas McLean was an employee of Merck. Rachael Batteson, Emma Hook, Anthony Hatswell and Hollie Wheat are employees of Delta Hat, who were paid consultants for Merck. Shobit Baijal received consulting fees for advisory boards from Merck. Paul Paik holds an advisory role with IDEOlogy, Touch IME, Excerpta Medica, ACE Oncology, Physicians Education Resource, Medscape, Agile, Axis Medical Education, PeerVoice, Aptitude Health, MJH, Annenberg Center and Cardinal Health; receives grants from EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA and Bicara; consulting fees from Novartis, Mirati, Janssen and Bicara; and his research institution receives research expenses from Celgene and EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data sets generated during and\/or analysed during the current study are not publicly available because of patient confidentiality and data ownership. Any requests for data by qualified scientific and medical researchers for legitimate research purposes will be subject to Merck\u2019s (CrossRef Funder ID: 10.13039\/100009945) Data Sharing Policy. All requests should be submitted in writing to Merck\u2019s data sharing portal ().","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"RB drafted the initial manuscript. RB, EH and HW constructed the model. AH performed the statistical analysis to implement in the model. SB and PP provided expert clinical insights. HV, TM and STA reviewed the initial model and provided input into the overall structure and assumptions, as well as contributing to the original health technology assessment submissions from which the model was based. Data for inclusion within the model were provided by HV, via the pivotal clinical trial and supportive data collection exercises. All authors reviewed each version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}